Mikhail Kirnus, MD
Cardiovascular Disease · Grand Forks, NDNPI 1922272228
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,859 of the $16,418 with a category attached, or 66.1%. It is spread thinly across 28 manufacturers, the largest accounting for just 21.9%. Reporting peaked in 2022 at $6,453 and has fallen 61.1% since, to $2,510 in 2025.
Across 414 payments — averaging $39.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$4K
- Shockwave Medical, Inc$3K
- Merit Medical Systems Inc$2K
- Boston Scientific$2K
- Medtronic$2K
- Abiomed$959
- plus $3K from 22 others
What the payments were for
- Travel & lodging$5,55534%
- Food & beverage$10,85966%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 27 | $3,590 |
| Shockwave Medical, Inc | 159 | $3,477 |
| Merit Medical Systems Inc | 6 | $1,852 |
| Boston Scientific | 122 | $1,704 |
| Medtronic(2 entities) | 20 | $1,535 |
| Abiomed | 9 | $959 |
| Philips North America LLC | 7 | $950 |
| Abbott | 13 | $587 |
| Opsens Inc. | 4 | $301 |
| Johnson & Johnson | 9 | $298 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 6 | $253 |
| Heartflow, Inc. | 1 | $144 |
| United Therapeutics Corporation | 1 | $88 |
| Cardinal Health 200 LLC | 1 | $86 |
| W. L. Gore & Associates, Inc. | 1 | $85 |
| E.r. Squibb & Sons, L.L.C. | 3 | $82 |
| AstraZeneca | 5 | $73 |
| Novartis | 4 | $68 |
| Angiodynamics, Inc. | 1 | $60 |
| Sanofi-aventis U.S. LLC | 4 | $57 |
| Lundbeck LLC | 3 | $45 |
| Amgen | 2 | $26 |
| Boehringer Ingelheim | 1 | $25 |
| Terumo Medical Corporation | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $16 |
| Lantheus Medical Imaging, Inc. | 1 | $15 |
| Cardiovascular Systems Inc. | 1 | $14 |
| Aegerion Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prelude Ideal Hydrophilic Sheath Introducer$1,613
- PreludeSync EZ Radial Compression Device$1,613
- PreludeSync Distal$1,613
- Edwards SAPIEN 3 Transcatheter Heart Valve$734
- (9520) IGT Devices Undivided$613
- Impella$522
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$329
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$266
- (6366) Sync$226
- DRAGONFLY OPSTAR$181
- Dragonfly OCT$176
- Micra$154
- FFRct$144
- COREVALVE EVOLUT R$143
- AMPLIA MRI QUAD CRT-D SURESCAN$138
- WATCHMAN FLX$134
- XARELTO$124
- LINQ II$113
- Reveal LINQ$108
- CoreValve Evolut$100
How this compares
$16,418 in reported general payments places this provider in the 85th percentile of 35 cardiovascular disease providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 99 | $70,127 |
| XareltoRivaroxaban | 26 | $18,345 |
| EntrestoSacubitril/Valsartan | 20 | $15,860 |
| FarxigaDapagliflozin Propanediol | 20 | $15,800 |
| BrilintaTicagrelor | 28 | $13,802 |
| JardianceEmpagliflozin | 14 | $8,108 |
| Atorvastatin Calcium | 307 | $2,231 |
| Losartan Potassium | 262 | $1,648 |
| Metoprolol Succinate | 120 | $1,470 |
| ClopidogrelClopidogrel Bisulfate | 119 | $1,349 |
| Ezetimibe | 48 | $1,327 |
| Amlodipine Besylate | 107 | $425 |
| Amiodarone Hcl | 19 | $394 |
| Chlorthalidone | 50 | $318 |
| Lisinopril | 89 | $307 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta | $73 | $29,60248 claims |
| Johnson & JohnsonXarelto | $298 | $18,34526 claims |
| NovartisEntresto | $68 | $15,86020 claims |
| Boehringer IngelheimJardiance | $25 | $8,10814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 35 cardiovascular disease providers in North Dakota.
Other cardiovascular disease in Grand Forks
- Noah ChelliahGrand Forks$115K
- Hussain BasrawalaGrand Forks$40K
- Rabeea AboufakherGrand Forks$14K
- Mohamed ChebacloGrand Forks$7K
- Puvanalingam AyyaduraiGrand Forks$3K
- Abdelhamid AhmedGrand Forks$17
- Beng Loong Isaac TeaMinot$42K
- Thomas HaldisFargo$37K
- Matthew GlogozaFargo$36K
- Timothy PansegrauBismarck$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.